Cerecin closes Series IIB financing to advance CER-0001 clinical programs and build pipeline in neuro-metabolism drug development

Cerecin

Series IIB Financing was supported by existing and new investors in South Korea.
Proceeds strengthen Cerecin’s operating position to advance the clinical studies of CER-0001 in migraine and infantile spasms.
New funds will also be used to build Cerecin’s pipeline and advance plans for a pivotal trial in Alzheimer’s disease.

SINGAPORE and DENVER, Sept. 28, 2022 (GLOBE NEWSWIRE) -- Cerecin Inc., a clinical-stage biotechnology company pioneering innovative neurotherapeutics, today announced it has successfully closed the first tranche of a Series IIB financing round led by prominent investors from South Korea. SK Securities and KNT Investment led the round. The funds raised will be used to advance the current clinical studies of CER-0001 in migraine prevention and in infantile spasms (a rare form of pediatric epilepsy), finalize plans for a pivotal study of CER-0001 in Alzheimer’s disease, and build Cerecin’s pipeline of innovative products designed to address metabolic targets in neurological diseases.

“We are delighted to have the support of new and existing investors who share in Cerecin’s vision to build a portfolio of innovative products that target the metabolic basis of neurological disease. This investment reflects increasing interest in this new frontier of neuroscience and the industry’s impetus for novel targets,” said Dr Charles Stacey, President and CEO of Cerecin. “Series IIB constitutes the next step in a path that we have defined, to fund our activities through a series of inflection points, as we work towards the launch of our pivotal programs.”

The successful financing follows the completion of enrollment of the RELIEF pilot study of CER-0001 as an investigational therapy for migraine prevention. The study enrolled 83 patients in Australia. The company is due to announce topline data later this month with a presentation at a scientific meeting. Cerecin continues to enroll patients in a pilot study in infantile spasms that has recently been expanded to include new clinical trial sites in Australia and Singapore.

Mr KiKab Kim, Managing Partner of K&T Investment and Board Director of Cerecin, commented: “Cerecin’s innovations in neurometabolism are exciting and define a new space for a neurology biotechnology company. We are pleased to support Cerecin’s objectives in unlocking much-needed solutions for patients suffering from diseases of the brain.”

Dr. Hans-Juergen Woerle, Chief Medical Officer and Chief Scientific Officer at Nestlé Health Science, commented: “Nestlé is pleased to be part of the continued progress made by Cerecin. We are excited to partner with new investors who share the vision of building a company in the field of neurometabolism. Deficiencies in cellular energetics and metabolism are recognised to be fundamental to a wide range of neurological diseases. Cerecin is on the right path.”

Cerecin closed a USD $40 million Series II and IIA Round in the 4^th quarter of 2021 following a cornerstone investment made by long-term investor, Nestlé. The Series IIA was led by SK Securities, Hana Financial Investment, and Partners Investment.

About Cerecin

Cerecin is a clinical-stage biotechnology company focused on developing drugs that target the metabolic bases of central nervous system diseases. Cerecin’s development program leverages its extensive experience in neurology drug development and lipid science. Cerecin is supported by two multinational partners, Nestlé S.A. (NSRGY), and Wilmar International Limited. By bringing together the deep expertise of its leadership team and a highly differentiated drug development program, Cerecin is becoming a global leader in neurology therapeutics.

This press release contains “forward-looking statements” under applicable securities laws that are based on the current expectations and beliefs of Cerecin. Such statements may be accompanied by words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “intend,” “may,” “plan,” “potential,” “possible,” “will” and other words and terms of similar meaning. All statements, except for statements of historical fact, are statements that could be deemed forward-looking statements, including but not limited to: (i) sources and availability of third party financing and investments and the projected financial performance of the Company; (ii) the expected development of the Company’s business, projects, drug development programs and joint ventures; (iii) execution of the Company’s vision and growth strategy, including with respect to future growth; and (iv) new developments with respect to the Company’s projects that are currently underway, in development or otherwise under consideration. Drug development and commercialization involve a high degree of risk, and only a small number of research and development programs result in commercialization of a product. Results in early stage clinical trials may not be indicative of full results or results from later stage or larger scale clinical trials and do not ensure regulatory approval. Forward-looking statements are not guaranties of future performance and undue reliance should not be placed on them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from projections of future performance or any result that may be expressed or implied by such forward-looking statements. Although forward-looking statements contained in this press release are based upon what management of Cerecin believes are reasonable assumptions, there can be no assurance or guarantee that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Cerecin undertakes no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements.

For more information visit www.cerecin.com.

For further information, please contact:

Emma Thompson

PR@cerecin.com

© 2022 Cerecin AC-22-955 09/22